Mood Disorders@@@Psychopharmacology
Michael Thase, MD
Professor of Psychiatry
Perelman School of Medicine of the University of Pennsylvania
Perelman School of Medicine at the University of Pennsylvania SOM
Philadelphia, Pennsylvania
The results of STAR*D drove home the limited efficacy of many of our favorite treatments in real world settings. In the post-STAR*D era, there has been increasing use of second-generation antipsychotics as adjuncts to antidepressants, despite some concerns about tolerability and longer-term safety. With the third decade of the 21st century just around the corner, a new generation of adjunctive therapies that target novel mechanisms are under investigation. This session will focus on the various combinations of medications that have been used to treat clinical depressions over the past 50 years, as well as those that may become state-of-the-art in the near future.